VeriSilicon and Innobase Collaboratively Launched Second-Generation Yunbao Series 5G RedCap/4G LTE Dual-Mode Modem IP
23.1.2025 01:00:00 CET | Business Wire | Press release
Advancing cellular mobile communication technology innovation and accelerating the lightweight 5G application adoption
VeriSilicon (688521.SH) today announced the joint launch of the second-generation Yunbao series 5G RedCap/4G LTE dual-mode modem IP, Yunbao 2, in collaboration with Innobase, a wireless communication technology and chip provider. This new modem IP has successfully completed production validation.
The newly launched modem IP integrates and reuses 4G and 5G hardware accelerators, delivering industry-leading performance in terms of area and power consumption. This IP complies with the 3GPP 5G Rel-17 standard and supports both 5G RedCap and 4G LTE FDD/TDD, achieving uplink and downlink transmission rates of 170 Mbps and 120 Mbps, respectively. It also supports multi-SIM standby and features key 5G capabilities such as Ultra-Reliable Low Latency Communication (URLLC), 5G LAN, and network slicing. Furthermore, chips developed using the Yunbao 2 modem IP can be paired with Innobase’s production-validated high-performance dual-mode RF chips, enabling seamless product-level integration and significantly accelerating the commercialization process for customers.
Under the guidance and organization of the IMT-2020 (5G) Promotion Group, the Yunbao series has successfully completed 5G RedCap terminal equipment and field performance testing with Nokia Shanghai Bell and ZTE. Additionally, it has completed interoperation tests between 5G RedCap terminals and base stations in collaboration with partners. These tests were conducted strictly adhering to the standards set by the Promotion Group, covering the full range of 5G RedCap terminal functionalities and performance metrics. The results thoroughly validated the overall capabilities of the Yunbao series, as well as its seamless interoperability with multiple network equipment vendors.
“The commercialization of RedCap in China has entered a rapid growth phase. As a new 5G variant defined under the 3GPP Rel-17 standard, RedCap features low cost, low latency, private network, and efficient spectrum utilization, making it an ideal solution for wearable devices, industrial IoT, and mass-market smartphones,” said Lu Wenbo, Senior Vice President of Innobase. “Innobase has introduced a variety of mass-production-ready products, including 5G IoT modules, MiFi devices, and mass-market 5G smartphones, which have successfully validated the Yunbao series IP at the product level. In the future, Innobase will leverage its extensive expertise in cellular communication technologies to develop the Yunbao X series featuring ultra-low-cost and ultra-low-power designs, to address the needs of consumer electronics and IoT applications. With the RedCap market rapidly evolving, we are excited to collaborate with VeriSilicon to deliver more advanced 5G multi-mode modem IP solutions to our customers.”
“The cost and performance of 5G RedCap chips are comparable to those of 4G, further expanding the boundaries of existing 4G application scenarios,” said Wiseway Wang, Executive Vice President, General Manager of Custom Silicon Platform Division of VeriSilicon. “Through our collaboration with Innobase, VeriSilicon is able to offer production-validated 4G/5G RedCap dual-mode IPs, further strengthening our existing IP ecosystem. VeriSilicon remains committed to driving innovation in low-power, high-performance wireless communication technologies, providing comprehensive wireless communication solutions, including RF, baseband, and protocol stacks, for IoT applications. Looking ahead, VeriSilicon will continue working closely with industry partners to build a global cellular communication ecosystem and contribute to an intelligent, connected future.”
About Innobase
Innobase is a leading fabless chip design company for cellular mobile communications. It designs chipset of 4G/5G and future 6G, including Baseband, RF, and PMIC for mobile terminals. Its dual mode chipset of 4G LTE/5G RedCap is commercialized with customers including telecom operators, IoT module makers, and mobile phone IDHs/ODMs. For more information, please visit: www.innobase.com.cn
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121582002/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom